Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma

Cancer

Volumn 117, Issue 20, 2011, Pages 4659-4670

  Huber, Gerhard F ^a   Albinger Hegyi, Andrea ^a   Soltermann, Alex ^a   Roessle, Matthias ^a   Graf, Nicole ^a   Haerle, Stephan K ^a   Holzmann, David ^a   Moch, Holger ^a   Hegyi, Ivan ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

B cell specific Moloney murine leukemia virus integration site 1; immunohistochemistry; oral and oropharyngeal squamous cell carcinoma; oral cavity; oropharynx; p16ink4a

Indexed keywords

BMI1 PROTEIN; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CELL NUCLEUS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959698390     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26100     Document Type: Article

References (50)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin. 1999; 49: 8-31.
2. Van Lohuizen M, Verbeek S, Scheijen B, et al. Identification of cooperating oncogenes in Emu-myc transgenic mice by provirus tagging. Cell. 1991; 65: 737-752. (Pubitemid 121001306)
3. Haupt Y, Alexander WS, Barri G, et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991; 65: 753-763. (Pubitemid 121001307)
4. Van Lohuizen M, Frasch M, Wientjens E, et al. Sequence similarity between the mammalian Bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature. 1991; 353: 353-355. (Pubitemid 21912509)
5. Brunk BP, Martin EC, Adler PN,. Drosophila genes posterior sex combs and suppressor 2 of zeste encode proteins with homology to the murine Bmi-1 oncogene. Nature. 1991; 353: 351-353. (Pubitemid 21912508)
6. Alkema MJ, Wiegant J, Raap AK, et al. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet. 1993; 2: 1597-1603. (Pubitemid 23358676)
7. Itahana K, Zou Y, Itahana Y, et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol. 2003; 23: 389-401. (Pubitemid 36008529)
8. van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-I proto-oncogene. Genes Dev. 1994; 8: 757-769.
9. Shakhova O, Leung C, Marino S,. Bmi1 in development and tumorigenesis of the central nervous system. J Mol Med. 2005; 83: 596-600. (Pubitemid 41176068)
10. Vonlanthen S, Heighway J, Altermatt HJ, et al. The Bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001; 84: 1372-1376. (Pubitemid 32522106)
11. Song LB, Zeng MS, Liao WT, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006; 66: 6225-6232.
12. Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002; 62: 4736-4745.
13. Zhang F, Sui L, Xin T,. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol. 2008; 30: 70-74. (Pubitemid 351518108)
14. Sawa M, Yamamoto K, Yokozawa T, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005; 82: 42-47. (Pubitemid 41512198)
15. Huang SD, Yuan Y, Liu XH, et al. Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal squamous cell carcinomas [serial online]. BMC Cancer. 2009; 9: 9.
16. Vrzalikova K, Skarda J, Ehrmann J, et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol. 2008; 134: 1037-1042.
17. Liu JH, Song LB, Zhang X, et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol. 2008; 97: 267-272. (Pubitemid 351312168)
18. Mihic-Probst D, Kuster A, Kilgus S, et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer. 2007; 121: 1764-1770. (Pubitemid 47417295)
19. Silva J, Garcia V, Garcia JM, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients [serial online]. Breast Cancer Res. 2007; 9: R55.
20. Vormittag L, Thurnher D, Geleff S, et al. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy. Int J Radiat Oncol Biol Phys. 2009; 73: 913-918.
21. Jacobs JJ, Scheijen B, Voncken JW, et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999; 13: 2678-2690. (Pubitemid 29508555)
22. Weber JD, Taylor LJ, Roussel MF, et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999; 1: 20-26. (Pubitemid 129495005)
23. Lowe SW, Sherr CJ,. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003; 13: 77-83. (Pubitemid 36143931)
24. Serrano M, Hannon GJ, Beach D,. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366: 704-707. (Pubitemid 24036021)
25. Sun Y, Deng D, You WC, et al. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. Clin Cancer Res. 2004; 10: 5087-5093. (Pubitemid 39099783)
26. ink4a confers susceptibility to metastatic melanoma in mice. Nature. 2001; 413: 83-86. (Pubitemid 32843492)
27. ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 2001; 413: 86-91. (Pubitemid 32843493)
28. Castellano M, Pollock PM, Walters MK, et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 1997; 57: 4868-4875. (Pubitemid 27468996)
29. Funk JO, Schiller PI, Barrett MT, et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol. 1998; 25: 291-296. (Pubitemid 28318933)
30. Vinarsky V, Fine RL, Assaad A, et al. Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck. 2009; 31: 1524-1527.
31. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994; 368: 753-756. (Pubitemid 24153417)
32. Scholes AG, Liloglou T, Maloney P, et al. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 2472-2477. (Pubitemid 32954850)
33. Mihic-Probst D, Mnich CD, Oberholzer PA, et al. p16 Expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2006; 118: 2262-2268.
34. Lindstrom MS, Klangby U, Inoue R, et al. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res. 2000; 256: 400-410. (Pubitemid 30244199)
35. Tan MC, Al Mushawah F, Gao F, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg. 2009; 198: 520-525.
36. van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001; 97: 3896-3901.
37. Hayry V, Makinen LK, Atula T, et al. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer. 2010; 102: 892-897.
38. He XT, Cao XF, Ji L, et al. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J Gastroenterol. 2009; 15: 2389-2394.
39. Silva J, Garcia JM, Pena C, et al. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res. 2006; 12: 6929-6936. (Pubitemid 44974485)
40. Schraml P, Hergovich A, Hatz F, et al. Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression. Am J Pathol. 2003; 163: 1013-1020. (Pubitemid 37040137)
41. Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 Positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010; 34: 1088-1096.
42. Hoffmann M, Ihloff AS, Gorogh T, et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer. 2010; 127: 1595-1602.
43. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer. 2010; 126: 1256-1262.
44. Jacobs JJ, Kieboom K, Marino S, et al. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999; 397: 164-168. (Pubitemid 29050921)
45. Kang MK, Kim RH, Kim SJ, et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer. 2007; 96: 126-133. (Pubitemid 46094649)
46. Studer G, Luetolf UM, Glanzmann C,. Locoregional failure analysis in head-and-neck cancer patients treated with IMRT. Strahlenther Onkol. 2007; 183: 417-423; discussion 424-425. (Pubitemid 47230517)
47. Albinger-Hegyi A, Stoeckli SJ, Schmid S, et al. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer. 2010; 126: 2653-2662.
48. Cueni LN, Hegyi I, Shin JW, et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 2010; 177: 1004-1016.
49. Huber GF, Fritzsche FR, Züïllig L, et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer. 2010 Nov 23 [Epub ahead of print].
50. Park I-K, Morrison SJ, Clarke MF,. Bmi1, stem cells, and senescence regulation. J. Clin. Invest. 2004; 113: 175-179. (Pubitemid 38544200)